Trial reportBioMed research international2016
A Nested Case-Control Study of Association between Metabolome and Hypertension Risk.
Trial report in BioMed research international, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 37 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
37 citing papers in PubMed, 1 synthesis or guideline pooled it, 50 citations in OpenAlex.
- Replication and mediation of the association between the metabolome and clinical markers of metabolic health in an adolescent cohort study.Scientific reports · 2023Pooled it
- Trial
- Association of plasma acylcarnitines and amino acids with hypertension: A nationwide metabolomics study.PloS one · 2023Trial
- Searching for Metabolic Markers for Hypertension in Human Urine.Molecules (Basel, Switzerland) · 2026Article
- Personalised approach to hypertension treatment: protocol for the HYPERMARKER randomised controlled trial.BMJ open · 2026Article
- Identification of Blood Pressure-Associated Metabolites by Integrating Metabolomic and Genetic Analysis.MedComm · 2026Article
- Metabolomics and Precision Medicine in Resistant Hypertension: Pathophysiological Insights, Biomarker Discovery, and Translational Strategies.International journal of hypertension · 2026Review
- A mechanistic study on the enhanced antihypertensive effects of aFrontiers in cell and developmental biology · 2026Article
- Nuclear Magnetic Resonance Analysis Seeking for Metabolic Markers of Hypertension in Human Serum.Molecules (Basel, Switzerland) · 2025Article
- Understanding Hypertension: A Metabolomic Perspective.Biology · 2025Review
- Gut microbiota on cardiovascular diseases-a mini review on current evidence.Frontiers in microbiology · 2025Review
- Causal Associations Between the Gut Microbiota and Hypertension-Related Traits Through Mendelian Randomization: A Cross-Sectional Cohort Study.Journal of clinical hypertension (Greenwich, Conn.) · 2025Article
- The Potential of Metabolomics as a Tool for Identifying Biomarkers Associated with Obesity and Its Complications: A Scoping Review.International journal of molecular sciences · 2024Article
- Unraveling the Role of the Human Gut Microbiome in Health and Diseases.Microorganisms · 2024Review
- Metabolomic Analyses to Identify Candidate Biomarkers of Cystinosis.International journal of molecular sciences · 2023Article
- Long-term use of probiotics for the management of office and ambulatory blood pressure: A systematic review and meta-analysis of randomized, controlled trials.Food science & nutrition · 2023Review
- Integrating transcriptomics and metabolomics to analyze the mechanism of hypertension-induced hippocampal injury.Frontiers in molecular neuroscience · 2023Article
- The role of the oral microbiome in smoking-related cardiovascular risk: a review of the literature exploring mechanisms and pathways.Journal of translational medicine · 2022Review
- Metabolome-Wide Association Study of Cord Blood Metabolites With Blood Pressure in Childhood and Adolescence.Hypertension (Dallas, Tex. : 1979) · 2022Article
- Serum metabolites of hypertension among Chinese adolescents aged 12-17 years.Journal of human hypertension · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
We aimed to explore novel small metabolites that associated with hypertension risk in a population-based nested case-control study. Among 460 individuals with optimal blood pressure (<120/80 mmHg) at baseline, 55 progressed to hypertension during 5 years of follow-up. Twenty-nine cases of incident hypertension and 29 controls, matched for age, sex, and baseline systolic blood pressure, were included in this study. Serum metabolites were measured by gas chromatography-tandem mass spectrometry. t-test and logistic regression analysis were applied to investigate the association between metabolites and incident hypertension. Among the 241 metabolites identified in this study, baseline levels of 26 metabolites were significantly different between hypertension and control groups. After adjusting for body mass index, smoking, and drinking, 16 out of the 26 metabolites were still associated with hypertension risk including four amino acids. Amino acids were negatively associated with risk of future hypertension, with odds ratio (OR) ranging from 0.33 to 0.53. Two of these amino acids were essential amino acids including threonine and phenylalanine. Higher level of lyxose, a fermentation product of gut microbes, was associated with higher risk of hypertension. Our study identified multiple metabolites that associated with hypertension risk. These findings implied that low amino acid levels and gut microbiome might play an important role in the pathogenesis of hypertension.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.